Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes

Anita Kumar, Irene A. Burger, Zhigang Zhang, Esther N. Drill, Jocelyn C. Migliacci, Andrea Ng, Ann LaCasce, Darci Wall, Thomas E. Witzig, Kay Ristow, Joachim Yahalom, Craig H. Moskowitz, and Andrew D. Zelenetz

Disclosures: 1. Information on support: Lymphoma Research Foundation Clinical Research Mentoring Program funding supported Dr. Anita Kumar's travel to Dana Farber Cancer Institute to perform measurements for validation cohort. Dr. Zhigang Zhang, biostatistician, receives funding from NIH Core Grant P30 CA008748. 2. Information on support received for work outside the submitted work: Anita Kumar: Pharmacyclics, Seattle Genetics, Celgene, Adaptive Biotechnologies. Irene Burger: None Zhigang Zhang: None Esther Drill: None Jocelyn Migliacci: None Andrea Ng: None Ann LaCasce: Seattle Genetics Darci Wall: None Thomas E. Witzig: Valeant Pharmaceuticals International, Amgen, Celgene, Novartis, Spectrum Pharmaceuticals, and Acerta Pharma. Kay Ristow: None Joachim Yahalom: None Craig Moskowitz: Merck, Seattle Genetics, Pharmacyclics, Genentech, Novartis. Andrew Zelenetz: Roche, GSK, Gilead, Celgene, Janssen, Hospira, Amgen, Medscape, Axess Oncology, Takeda Pharma, France Foundation, Bristol Myers, and Boehringer Ingelheim. 3. Information on patents or copyright: not applicable.

Contributions: AK, IAB, ZZ, END, JCM, AN, AL, DW, TEW, KR, JY, CHM, and ADZ contributed to the study design, data collection, data analysis, and data interpretation. The draft manuscript was written by AK and ADZ was commented upon and revised by all the authors.